Hansa Biopharma announces long term follow-up data demonstrating 3-year graft survival of 84% after imlifidase treatment and transplantation
· Three-year overall allograft survival was 84% in crossmatch positive patients treated with imlifidase. · In patients with a cPRA of ≥99.9%, three-year allograft survival was 92% · Data published in an article accepted by the American Journal of Transplantation Lund, Sweden July 9, 2021. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announced three-year follow-up data in crossmatch positive patients who received imlifidase prior to kidney transplantation.[1] As reported in the article, which has been